Literature DB >> 11245860

Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain.

A Siegling1, H A Hofmann, D Denzer, F Mauler, J De Vry.   

Abstract

Although cannabinoids are known to be more effective analgesics against chronic rather than acute pain, the mechanism underlying this phenomenon is still unclear. We report now that contralateral thalamic cannabinoid CB(1) receptors are upregulated after unilateral axotomy of the tibial branch of the sciatic nerve, a rat model of chronic neuropathic pain, and hypothesize that cannabinoid CB(1) receptor upregulation contributes to the increased analgesic efficacy of cannabinoids in chronic pain conditions.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11245860     DOI： 10.1016/s0014-2999(01)00798-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  33 in total

Review 1.  Role of cannabinoids in the management of neuropathic pain.

Authors:  M Isabel Martín Fontelles; Carlos Goicoechea García
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.

Authors:  Lydia K Miller; Lakshmi A Devi
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.

Authors:  Mark S Wallace; Thomas D Marcotte; Anya Umlauf; Ben Gouaux; Joseph H Atkinson
Journal:  J Pain       Date:  2015-04-03       Impact factor: 5.820

Review 4.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 7.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 8.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

9.  Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.

Authors:  B Costa; M Colleoni; S Conti; A E Trovato; M Bianchi; M L Sotgiu; G Giagnoni
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 10.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.